Some of the names on the move ahead of the open.
Covidien President & CEO Jose Almeida discusses why now is the best time to separate the pharma business. "Covidien has been growing above market," he says.
NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.
*Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.
NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.